Aldeyra TherapeuticsALDX
ALDX
About: Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
Employees: 8
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
100% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 2 (+1) [Q1 2025]
71% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 14
66% more call options, than puts
Call options by funds: $5.79M | Put options by funds: $3.49M
22% more capital invested
Capital invested by funds: $186M [Q4 2024] → $226M (+$40M) [Q1 2025]
6% more funds holding
Funds holding: 118 [Q4 2024] → 125 (+7) [Q1 2025]
1.0% more ownership
Funds ownership: 62.45% [Q4 2024] → 63.45% (+1.0%) [Q1 2025]
45% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 47
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$9
224%
upside
Avg. target
$9.50
242%
upside
High target
$10
260%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Matthew Caufield | 260%upside $10 | Buy Reiterated | 19 May 2025 |
BTIG Thomas Shrader | 224%upside $9 | Buy Maintained | 7 Apr 2025 |
Financial journalist opinion
Neutral
Business Wire
2 weeks ago
Aldeyra Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 2025 Jefferies Global Healthcare Conference in New York, New York. Dr. Brady's conversation with Clara Dong is scheduled to begin at 4:20 p.
Neutral
Accesswire
4 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
NEW YORK CITY, NY / ACCESS Newswire / May 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ:ALDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Neutral
Accesswire
1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
NEW YORK CITY, NY / ACCESS Newswire / May 14, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ:ALDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Neutral
GlobeNewsWire
1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aldeyra Therapeutics, Inc. – ALDX
NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) (NASDAQ: ALDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Neutral
PRNewsWire
1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
NEW YORK , May 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ: ALDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Neutral
Accesswire
1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
NEW YORK CITY, NY / ACCESS Newswire / May 10, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ:ALDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Neutral
Accesswire
1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
NEW YORK CITY, NY / ACCESS Newswire / May 8, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ:ALDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Neutral
Accesswire
1 month ago
ALDX INVESTIGATION NOTICE: Aldeyra Therapeutics, Inc. Investors are Notified of the Pending Securities Investigation; Contact BFA Law
NEW YORK, NY / ACCESS Newswire / May 7, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) for potential violations of the federal securities laws. If you invested in Aldeyra Therapeutics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/aldeyra-therapeutics-inc.
Neutral
GlobeNewsWire
1 month ago
ALDX SECURITIES UPDATE: Aldeyra Therapeutics Investors with Losses may have been affected by Securities Violations – Contact BFA Law (NASDAQ:ALDX)
NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for potential violations of the federal securities laws. If you invested in Aldeyra Therapeutics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/aldeyra-therapeutics-inc.
Neutral
Accesswire
1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
NEW YORK CITY, NY / ACCESS Newswire / May 7, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ:ALDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Charts implemented using Lightweight Charts™